Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

Autor: María A Esteve-Pastor, José M Rivera-Caravaca, Vanessa Roldán, Marcelo Sanmartin Fernández, Fernando Arribas, Jaime Masjuan, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Esther Recalde, Alejandro I Pérez-Cabeza, José Manuel Vázquez Rodríguez, Carles Ràfols Priu, Manuel Anguita Sánchez, Gregory Y H Lip, Francisco Marin

Publikováno v: Esteve-Pastor, M A, Rivera-Caravaca, J M, Roldán, V, Fernández, M S, Arribas, F, Masjuan, J, Barrios, V, Cosin-Sales, J, Freixa-Pamias, R, Recalde, E, Pérez-Cabeza, A I, Rodríguez, J M V, Priu, C R, Sánchez, M A, Lip, G Y H & Marin, F 2023, ' Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban : Observations from the prospective EMIR Registry ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 1, pp. 38-46 . https://doi.org/10.1093/ehjcvp/pvac060

Background Assessing bleeding risk during the decision-making process of starting oral anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding risk scores have been proposed for vitamin K antagonist users but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cbffcb0afd9e1a00c1add23c67a0313
https://doi.org/10.1093/ehjcvp/pvac060